Related Experiment Video
Updated: May 17, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Agents to treat osteoporosis in chronic kidney disease
1Department of Medicine, University of California, San Francisco, California, USA.
Insights
Managing osteoporosis in chronic kidney disease (CKD) patients requires personalized strategies. Bone turnover and mineral status guide treatment, but more research is needed for optimal skeletal outcomes in this high-risk group.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Patients with chronic kidney disease (CKD) face a significantly elevated risk of fractures.
- Diagnosing and treating osteoporosis in CKD patients presents unique complexities.
- Bone health management in CKD is critical due to increased fracture risk.
Purpose of the Study:
- To review current challenges in managing bone health for patients with CKD.
- To highlight emerging strategies for addressing CKD-associated osteoporosis.
- To identify gaps in the diagnosis and treatment of osteoporosis in this population.
Main Methods:
- Review of current literature on CKD-associated osteoporosis.
- Integration of diagnostic tools including imaging, bone turnover markers, and bone biopsy.
- Assessment of therapeutic strategies based on bone turnover status and mineral metabolism.
Main Results:
- Diagnosis involves a combination of imaging, biomarkers, and potentially biopsy.
- Correction of mineral metabolism is essential before initiating bone-specific therapies.
- Treatment selection includes antiresorptives (bisphosphonates, denosumab) for high turnover and osteoanabolic agents (teriparatide, romosozumab) for low turnover.
Conclusions:
- Individualized management based on bone turnover and mineral status is crucial for osteoporosis in CKD.
- Limited randomized trial evidence exists for pharmacologic options in CKD populations.
- Further research is necessary to refine treatment selection, establish safe targets, and enhance skeletal health outcomes.
Purpose Of Review:
Fracture risk is significantly elevated in patients with chronic kidney disease (CKD), yet the diagnosis and treatment of CKD-associated osteoporosis remain complex. This review addresses the current gaps in managing bone health in CKD and highlights emerging strategies in this high-risk population.
Recent Findings:
Diagnosis of CKD-associated osteoporosis requires integration of imaging, bone turnover markers, and occasionally bone biopsy. Correction of mineral metabolism disturbances is foundational, while bone-targeted therapies must be carefully selected. Treatment strategies are informed by bone turnover status. Antiresorptives such as bisphosphonates and denosumab are used in high-turnover disease, and osteoanabolic agents such as teriparatide and romosozumab are promising for low-turnover disease.
Summary:
Management of osteoporosis in CKD requires individualized approaches based on bone turnover and mineral metabolism status. While several pharmacologic options exist, evidence from randomized trials in CKD populations is limited. Further research is needed to guide treatment selection, define well tolerated therapeutic targets, and improve skeletal outcomes in this vulnerable group.
Related Concept Videos
01:40Bone Remodeling
01:31Osteoclasts in Bone Remodeling
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...